West Pharmaceutical Services (NYSE:WST) Releases FY 2026 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 8.400-8.750 for the period, compared to the consensus EPS estimate of 7.990. The company issued revenue guidance of $3.3 billion-$3.4 billion, compared to the consensus revenue estimate of $3.2 billion. West Pharmaceutical Services also updated its Q2 2026 guidance to 2.050-2.120 EPS.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Weiss Ratings restated a “hold (c)” rating on shares of West Pharmaceutical Services in a report on Friday, January 9th. Barclays boosted their target price on shares of West Pharmaceutical Services from $265.00 to $275.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 14th. Jefferies Financial Group restated a “buy” rating and issued a $295.00 target price on shares of West Pharmaceutical Services in a report on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $315.00 price target on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Finally, Evercore decreased their price objective on West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating for the company in a report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $315.67.

West Pharmaceutical Services Stock Up 12.8%

Shares of WST traded up $35.10 during trading hours on Thursday, reaching $309.51. 776,321 shares of the stock traded hands, compared to its average volume of 955,868. The company has a current ratio of 3.02, a quick ratio of 2.34 and a debt-to-equity ratio of 0.06. The stock has a fifty day simple moving average of $250.67 and a 200 day simple moving average of $261.77. West Pharmaceutical Services has a 52 week low of $199.89 and a 52 week high of $322.34. The company has a market cap of $22.31 billion, a price-to-earnings ratio of 45.58, a PEG ratio of 2.92 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. During the same period in the prior year, the business posted $1.45 earnings per share. The firm’s revenue was up 21.0% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, equities analysts forecast that West Pharmaceutical Services will post 7.91 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 6th. Stockholders of record on Wednesday, April 29th will be paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Wednesday, April 29th. West Pharmaceutical Services’s payout ratio is presently 12.96%.

West Pharmaceutical Services announced that its Board of Directors has approved a stock repurchase program on Tuesday, February 17th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to reacquire up to 5.6% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Trending Headlines about West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q1 results materially beat expectations: GAAP EPS of $2.13 vs. consensus ~$1.68 and revenue growth of ~21% year‑over‑year, signaling solid top‑line momentum. Zacks: Q1 beat
• Positive Sentiment: Company raised FY2026 guidance to EPS $8.40–$8.75 (above Street) and revenue target to $3.3–$3.4B, and raised Q2 EPS and revenue ranges — signaling management’s confidence in sustained demand. PR Newswire: Press release
• Positive Sentiment: Management attributes strength to continued demand for proprietary packaging components (syringes, cartridges) and growth in high‑value segments (including GLP‑1 and other injectables), which supports higher margins and recurring revenue. Seeking Alpha: demand drivers
• Neutral Sentiment: Company provided additional disclosure (press release, slide deck and conference call) for investors to assess segment performance and margins; listen/see slides for detail on geographic and product mix. Slide deck / press materials
• Negative Sentiment: Valuation is elevated after the move — trailing P/E near mid‑40s — which could limit near‑term upside if growth moderates or the macro backdrop weakens. MarketBeat: valuation & metrics

Hedge Funds Weigh In On West Pharmaceutical Services

Several institutional investors have recently bought and sold shares of WST. CYBER HORNET ETFs LLC purchased a new position in West Pharmaceutical Services in the 2nd quarter valued at approximately $25,000. DV Equities LLC bought a new position in shares of West Pharmaceutical Services in the fourth quarter worth $28,000. MUFG Securities EMEA plc purchased a new position in shares of West Pharmaceutical Services in the second quarter valued at $47,000. State of Wyoming purchased a new position in shares of West Pharmaceutical Services in the second quarter valued at $49,000. Finally, Meeder Asset Management Inc. raised its stake in shares of West Pharmaceutical Services by 1,023.5% during the 4th quarter. Meeder Asset Management Inc. now owns 191 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 174 shares during the period. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.